ASMBS 2026
Two-year costs lower for bariatric surgery vs GLP-1s in diabetes
Clinical takeaway: Cost discussions with patients weighing obesity treatment should extend beyond the immediate drug price to include long-term maintenance and payer coverage considerations.
GLP-1 medications carry lower upfront costs than surgery, but their long-term financial implications often remain unclear. This real-world analysis compared total two-year costs for GLP-1 therapy versus bariatric surgery in patients with obesity and type 2 diabetes, factoring in expenses tied to unresolved obesity-related conditions.
Surgery proved less costly than GLP-1 therapy. Total two-year costs were about $17,000 lower for sleeve gastrectomy than GLP-1 treatment ($41,400 vs. $58,600) and roughly $7,200 lower for gastric bypass ($51,300 vs. $58,600). Costs varied by insurance type.
The findings push back on the common assumption that medications are the more cost-effective option because of lower upfront pricing. Once durability, adherence, and the cost of unresolved comorbidities are included over time, the economics shift. Patients who discontinue GLP-1 therapy, which is common in real-world use, may also continue to incur costs related to weight regain and persistent metabolic disease.
The cost difference reflects both treatment pricing and downstream care for obesity-related conditions like type 2 diabetes, hypertension, and cardiovascular disease, where surgery's durability may reduce long-term spending.
The analysis drew on an all-payer claims database covering nearly 91,000 adults with obesity and type 2 diabetes treated between 2017 and 2023. GLP-1 patients were matched with similar patients who underwent either sleeve gastrectomy or gastric bypass, with roughly 4,000 to 5,000 patients for each surgery type. The study was funded through a collaboration with Intuitive Surgical, a surgical robotics company that paid for database access, and has not yet undergone full peer review.
The two-year window alone doesn't provide the full cost picture. GLP-1 therapy is intended to continue indefinitely, so cost differences could widen further over longer follow-up.
"Obesity is a chronic disease and treatment decisions must consider long-term outcomes, affordability and sustainability," said Richard Peterson, MD, MPH, FASMBS, president of the American Society for Metabolic and Bariatric Surgery and professor of surgery at UT Health San Antonio, who was not involved in the study. "In this particular study, the more durable and clinically effective treatment — metabolic and bariatric surgery — is also the more affordable one."
Source: Edwards M. ASMBS 2026 Annual Scientific Meeting Abstract 4339. Understanding insurance-based differential healthcare costs for GLP-1 RA versus bariatric surgery